Skip to main content

Table 2 Characteristics of ALT responders and non-responders

From: Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

 

ALT responders (n = 15)

ALT non-responders (n = 14)

P-value

Age (year)

50.7 ± 12.1

61.7 ± 12.4

0.011

Male/female (n)

9 (6)

5 (9)

0.191

Dyslipidemia (%)

12 (80.0)

12 (85.7)

0.68

Statin (%)

4 (26.7)

8 (57.1)

0.10

Diabetes (%)

5 (33.3)

9 (64.3)

0.10

BMI (kg/m2)

26.5 ± 4.1

26.6 ± 3.8

0.47

FBS (mg/dL)

115.7 ± 37.9

121.4 ± 31.2

0.33

IRI (μU/mL)

23.5 ± 22.7

22.6 ± 38.0

0.47

HbA1c (%)

5.94 ± 1.03

6.9 ± 1.2

0.019

HDL cholesterol (mg/dL)

60.3 ± 18.6

49.7 ± 11.7

0.04

LDL cholesterol (mg/dL)

124.5 ± 33.1

102.9 ± 18.6

0.021

Triglycerides (mg/dL)

202.4 ± 164.1

187.6 ± 103.3

0.39

NEFA (μEq/L)

720.2 ± 285.0

563.3 ± 143.0

0.055

AST (IU/L)

46.3 ± 20.2

47.1 ± 14.1

0.45

ALT (IU/L)

77.1 ± 38.6

60.1 ± 32.2

0.104

GGT (IU/L)

81.9 ± 58.0

58.0 ± 26.6

0.085

Ferritin (ng/mL)

260.2 ± 164.5

176.6 ± 126.1

0.07

Platelet count (×104 /μL)

20.3 ± 4.6

21.3 ± 6.8

0.32

Type IV collagen 7 s

4.61 ± 1.13

5.59 ± 2.51

0.09

Glutathione in protein fraction (μM)

1.53 ± 0.92

1.27 ± 0.83

0.230

Glutathione in deprotenized fraction (μM)

0.017 ± 0.020

0.036 ± 0.057

0.116

CAP (db/m)

300.3 ± 41.1

290.4 ± 50.2

0.29

LSM (kPa)

8.71 ± 4.63

11.36 ± 5.05

0.080

  1. Data are expressed as mean ± standard deviation
  2. Abbreviations: BMI body mass index, FBS fasting blood sugar, IRI immunoreactive insulin, HBA1c hemoglobin A1c, HDL cholesterol high density lipoprotein cholesterol, LDL cholesterol low density lipoprotein cholesterol, NEFA non-esterified fatty acid, AST asparate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, CAP controlled attenuation parameter, LSM liver stiffness measurement